Phase 3 Lung Cancer Trial, Recruiting NCT07034326 Sponsor: Kong Fanming Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT07034326
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of lung cancer (non-small cell lung cancer, at stage II, IIIA, or IIIB with lymph node involvement) confirmed by a lab test after surgery, and the cancer has not spread to other parts of the body
  • Your cancer does not have certain genetic changes (called "driver mutations") that affect how it grows
  • You have already completed between 1 and 4 rounds of chemotherapy after your surgery
  • You have been assessed by a traditional Chinese medicine practitioner and found to have a specific pattern of symptoms known as "two qi syndrome" (confirm with trial site)
  • You are between 18 and 80 years old
  • Your doctors expect you to live for more than 6 months
  • You are able to carry out basic daily activities with little or no difficulty (this is measured on a standard scale called ECOG, scoring 0 to 2)
  • You are willing to follow the treatment plan and attend all required appointments

Who may not be able to join:

  • You have been diagnosed with any other type of cancer in the past 5 years, or have another cancer at the same time
  • You have serious problems with your heart, liver, or kidneys, or other serious health complications
  • Your surgery did not remove all of the cancer (known as R1 or R2 resection), or you need radiation therapy after your surgery
  • You have a diagnosed mental health disorder
  • You have a history of allergies to multiple medications, or are generally prone to allergic reactions
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Kong Fanming
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease free survival(DFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov